Mark Downey, MD
Interventional Pain Management · Birmingham, ALNPI 1477507648
Payments from drug & device makers
Across 81 payments — averaging $23.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$515
- Abbott$380
- Nevro Corp.$259
- Globus Medical$188
- Curonix LLC$98
- Vertos Medical, Inc.$91
- plus $376 from 12 others
What the payments were for
- Food & beverage$1,907100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 23 | $515 |
| Abbott | 21 | $380 |
| Nevro Corp. | 6 | $259 |
| Globus Medical | 5 | $188 |
| Curonix LLC | 1 | $98 |
| Vertos Medical, Inc. | 3 | $91 |
| IBSA Pharma Inc. | 3 | $59 |
| Si-bone, Inc. | 3 | $45 |
| Baxter Healthcare | 2 | $39 |
| Saluda Medical Americas, Inc. | 2 | $39 |
| Amgen(2 entities) | 2 | $34 |
| Stimwave Technologies Incorporated | 2 | $30 |
| Pfizer | 2 | $28 |
| Biotronik NRO, Inc. | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Vertex | 1 | $22 |
| Avanos Medical | 1 | $17 |
| Zyla Life Sciences, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza$131
- WaveWriter Alpha Prime 16$113
How this compares
Too few interventional pain management providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 349 | $3,316 |
| Lidocaine | 24 | $2,967 |
| Celecoxib | 105 | $1,838 |
| Methocarbamol | 137 | $1,318 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 160 | $709 |
| Tizanidine Hcl | 91 | $652 |
| Tramadol Hcl | 246 | $554 |
| Cyclobenzaprine Hcl | 52 | $524 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 47 | $293 |
| Methylprednisolone | 34 | $273 |
| Meloxicam | 42 | $203 |
| Diclofenac Sodium | 11 | $197 |
| Diazepam | 11 | $8 |
Paid to pharmacies, not to this prescriber.
Other interventional pain management in Birmingham
- Norman McCoomerMadison$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.